Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2b Randomized Double-blind, Placebo-controlled Trial to Estimate the Potential Efficacy and Safety of Two Repurposed Drugs, Acetylsalicylic Acid and Ibuprofen, for Use as Adjunct Therapy Added to, and Compared With, the Standard WHO-recommended TB Regimen (SMA-TB)

NCT04575519 is registered in ClinicalTrials.gov with Fundació Institut Germans Trias i Pujol as lead sponsor.

NCT NCT04575519
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04575519 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2b Randomized Double-blind, Placebo-controlled Trial to Estimate the Potential Efficacy and Safety of Two Repurposed Drugs, Acetylsalicylic Acid and Ibuprofen, for Use as Adjunct Therapy Added to, and Compared With, the Standard WHO-recommended TB Regimen (SMA-TB)
Lead sponsor
Fundació Institut Germans Trias i Pujol
Phase
Phase 2
Overall status
Terminated
Start date
March 4, 2021
Completion date
March 4, 2024
Enrollment
426 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

tuberculosis infection, tuberculosis, mdr, tuberculosis, pulmonary